Concepedia

C. van Arkel

CV

Statistics

Publications

8

Citations

255

H-Index

8

Active since

1963

Affiliations

St. Antonius Ziekenhuis(Current)

University Medical Centre Mannheim

Universitätsklinikum Erlangen

Praxis für Hämatologie und Onkologie

University Hospital Heidelberg

C. van Arkel is an author at St. Antonius Ziekenhuis specializing in medicine, open-label trials, and metastatic renal cell carcinoma therapy.

Publications per year

1963–2015

8

Publications

8

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer

Christian Eichelberg, Walter L. Vervenne, Maria De Santis et al. · European Urology · 2015 · 142 citations · Full text

Medicine, Oncology, Pharmacology +16

SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

Maurice Stephan Michel, Walter L. Vervenne, Maria De Santis et al. · Journal of Clinical Oncology · 2014 · 44 citations

Medicine, Oncology, Pharmacotherapy +17

Micro-electrophoresis of mucopolysaccharides on agarose gel

C. van Arkel, R. E. Ballieux, F. L. J. Jordan · Journal of Chromatography A · 1963 · 13 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +6

Thrombosis and bleeding disorders. Theory and methods

C. van Arkel · European Journal of Obstetrics & Gynecology · 1972 · 12 citations

Medicine, Hematology, Hemostasis +9

Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

Peter J. Goebell, Walter L. Vervenne, Maria De Santis et al. · Journal of Clinical Oncology · 2014 · 12 citations

Medicine, Oncology, Pharmacology +15

1–5 of 8